title: Comparing ELISA and surface plasmon resonance for assessing clinical immunogenicity of panitumumab.
abstract: Evaluation of the immunogenicity of panitumumab, a fully human anti-epidermal growth factor receptor mAb approved for use in colorectal cancer patients, led to the development of two separate immunoassays for the detection of anti-panitumumab Abs. The first immunoassay used a bridging ELISA capable of detecting 10 ng/ml positive control anti-panitumumab Ab. The ELISA incorporated an acid dissociation step to reduce drug interference and tolerated the presence of approximately 100-fold molar excess of drug. During eight clinical trials, the ELISA detected developing Ab responses in 2 of 612 (0.3%) subjects. In one of the ELISA positive subjects, neutralizing Abs were detected using an epidermal growth factor receptor phosphorylation bioassay. The second immunoassay used a Biacore biosensor immunoassay format capable of detecting 1 mug/ml positive control Ab while tolerating the presence of equal molar amounts of drug. Although less sensitive and less tolerant to competing drug in the assay, the Biacore assay detected developing Ab responses in 25 of the 604 (4.1%) subjects. Additionally, the Biacore assay identified eight subjects who developed neutralizing Abs. Mouse mAbs with affinities ranging from 1.1 x 10(-6) to 8.4 x 10(-10) M were used to characterize both assay types. The ELISA was more sensitive for the detection of higher affinity mAbs and detected high-affinity mAbs in the presence of higher molar ratio of drug to mAb. The Biacore assay was more sensitive for detection of lower affinity mAbs and detected low affinity Abs in the presence of higher molar ratios of drug to mAb.
authors.affiliation: Department of Clinical Immunology, Amgen, Thousand Oaks, CA 91320, USA.
authors.forename: James A
authors.initials: JA
authors.lastname: Lofgren
authors.forename: Sripriya
authors.initials: S
authors.lastname: Dhandapani
authors.forename: Jason J
authors.initials: JJ
authors.lastname: Pennucci
authors.forename: Christina M
authors.initials: CM
authors.lastname: Abbott
authors.forename: Daniel T
authors.initials: DT
authors.lastname: Mytych
authors.forename: Arunan
authors.initials: A
authors.lastname: Kaliyaperumal
authors.forename: Steven J
authors.initials: SJ
authors.lastname: Swanson
authors.forename: Michael C
authors.initials: MC
authors.lastname: Mullenix
mesh_terms: D000818:Animals; D000888:Antibodies, Anti-Idiotypic / Q000096:biosynthesis / Q000097:blood; D000911:Antibodies, Monoclonal / Q000008:administration & dosage* / Q000276:immunology* / Q000378:metabolism; D000915:Antibody Affinity; D045744:Cell Line, Tumor; D004306:Dose-Response Relationship, Immunologic; D004797:Enzyme-Linked Immunosorbent Assay / Q000379:methods* / Q000592:standards; D018604:Epitope Mapping; D066246:ErbB Receptors / Q000276:immunology; D005260:Female; D006801:Humans; D007074:Immunoglobulin G / Q000096:biosynthesis / Q000378:metabolism; D051379:Mice; D016688:Mice, Inbred NOD; D000077544:Panitumumab; D012680:Sensitivity and Specificity; D020349:Surface Plasmon Resonance / Q000379:methods* / Q000592:standards
chemical_list: D000888:Antibodies, Anti-Idiotypic; D000911:Antibodies, Monoclonal; D007074:Immunoglobulin G; D000077544:Panitumumab; D066246:ErbB Receptors